AU2001230920A1 - Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1 - Google Patents

Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1

Info

Publication number
AU2001230920A1
AU2001230920A1 AU2001230920A AU3092001A AU2001230920A1 AU 2001230920 A1 AU2001230920 A1 AU 2001230920A1 AU 2001230920 A AU2001230920 A AU 2001230920A AU 3092001 A AU3092001 A AU 3092001A AU 2001230920 A1 AU2001230920 A1 AU 2001230920A1
Authority
AU
Australia
Prior art keywords
lfa
icam
diagnosis
inhibiting
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001230920A
Inventor
Sherman Fong
Kenneth J. Hillan
Wyne Pun Lee
Daniel B. Tumas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2001230920A1 publication Critical patent/AU2001230920A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
AU2001230920A 2000-01-14 2001-01-12 Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1 Abandoned AU2001230920A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17885900P 2000-01-14 2000-01-14
US60178859 2000-01-14
PCT/US2001/001050 WO2001051084A1 (en) 2000-01-14 2001-01-12 Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1

Publications (1)

Publication Number Publication Date
AU2001230920A1 true AU2001230920A1 (en) 2001-07-24

Family

ID=22654195

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001230920A Abandoned AU2001230920A1 (en) 2000-01-14 2001-01-12 Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1

Country Status (2)

Country Link
AU (1) AU2001230920A1 (en)
WO (1) WO2001051084A1 (en)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284931A (en) * 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
ES2080044T3 (en) * 1987-05-04 1996-02-01 Dana Farber Cancer Inst Inc INTERCELLULAR ADHESION MOLECULES AND THEIR FIXATION LINKS.
JPH04505009A (en) * 1989-03-09 1992-09-03 ダナ・ファーバー・キャンサー・インスティチュート Cloning LFA-1
ATE143376T1 (en) * 1989-06-02 1996-10-15 Univ Johns Hopkins Med MONOCLONAL ANTIBODIES DIRECTED AGAINST THE BETA CHAIN OF THE LEUKOCYTE ADHESION RECEPTOR, METHOD FOR THEIR PRODUCTION AND THEIR USE
US5223396A (en) * 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
EP0610298A1 (en) * 1991-10-01 1994-08-17 The General Hospital Corporation Preventing allograft rejection with antibodies to adhesion molecules
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
FR2700471B1 (en) * 1993-01-21 1995-04-07 Pasteur Merieux Serums Vacc Use of anti-LFA-1 monoclonal antibodies for the preparation of a medicament intended to prevent rejection of solid organ transplants and medicaments obtained.
EP0762886A4 (en) * 1994-04-19 1999-03-31 Univ Kansas Icam-1/lfa-1 short-chain peptides and method of using same
US5747035A (en) * 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
IL130143A0 (en) * 1996-11-27 2000-06-01 Genentech Inc Humanized anti-CD11a antibodies
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
UA74781C2 (en) * 1999-04-02 2006-02-15 Abbott Lab Antiinflammatory and immumosuppressive compounds inhibiting cell adhesion

Also Published As

Publication number Publication date
WO2001051084A1 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
WO2003034984A9 (en) Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
AU9287401A (en) Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
AU2003213606A8 (en) Mp53s as modifiers of the p53 pathway and methods of use
IL142908A0 (en) Compounds useful in the treatment of inflammatory diseases
EP1402053A4 (en) CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
EP1421384A4 (en) Hprp4s as modifiers of the p53 pathway and methods of use
AU2001264932A1 (en) Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
AUPR074500A0 (en) Treatment of t cell disorders
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU7601400A (en) Treatment and prevention of hepatic disorders
AU2001229597A1 (en) Compositions and methods to treat neurodegenerative disorders
AU2001267404A1 (en) Novel compounds for the treatment of inflammatory and cardiovascular diseases
AU4808700A (en) Use of topical azathioprine to treat inflammatory bowel disorders
AU2001283199A1 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
EP1613318A4 (en) Compounds and their use to treat diabetes and related disorders
AU2001230920A1 (en) Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
ITRM990707A0 (en) COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF DISORDERS DUE TO ALTERED METABOLISM OF LIPIDS, WHICH INCLUDES PROPIONIL L-MEATS
AU2001256998A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
AU2001251508A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
HK1025894A1 (en) Hydroxamic acid derivatives as inhibitors of the production of human cd23 and of the tnf release.
HUP0204209A3 (en) Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms
AU2003303094A8 (en) Mat2as as modifiers of the p53 pathway and methods of use
AU2002332130A1 (en) Msrebps as modifiers of the srebp pathway and methods of use
AU3604100A (en) Methods for enhancing the disease resistance of plants